Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio

Vyome seeks to access multi-billion-dollar AI-enabled medical device market

CAMBRIDGE, Mass. & PUNE, India, August 21, 2025–(BUSINESS WIRE)–Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, and Embryyo Technologies today announced the signing of an MoU (Memorandum of Understanding) to jointly pursue the global AI-enabled medical device market. This partnership will combine Vyome’s healthcare industry experience and resources with Embryyo’s medical technology capabilities to potentially productize and commercialize smart medical devices that can transform the standard-of-care in disease management and treatment.

“Vyome’s vision is to partner with the smartest talent tackling the biggest healthcare markets along the US-India corridor and across our three pillars of pharma, AI, and medical devices. AI-enabled medical devices represent a large opportunity and the Embryyo team – helmed by Indian Institutes of Technology (IIT) alums – has been working in this sector for a decade. We will be working with them to identify the specific initiatives on which we will partner,” said Krishna Gupta, Chairman of Vyome Holdings.

“We are excited about this partnership with Vyome as we have a shared vision. We are currently developing a portfolio of transformative medical devices spanning interventional oncology, surgery, wearables, and drug delivery, and Vyome’s access to global capital markets and the U.S. healthcare ecosystem will accelerate our mission to push the frontiers of medicine and elevate standards of care in healthcare globally,” said Nishant Kumar, Co-Founder and CEO of Embryyo Technologies.

As part of this partnership, Vyome and Embryyo will host a global AI-enabled medical device innovation forum for companies along the US-India corridor. The MoU is non-binding and may be subject to other conditions.

About Vyome

Vyome is building the world’s premier platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome’s immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit www.vyometx.com.

About Embryyo

Embryyo is a medical device innovation studio which specializes in unmet clinical need discovery and validation, ideation, IP creation, early-stage technology de-risking and medical device product development. Over the years, Embryyo has worked with a diverse global clientele including med-tech MNC’s, inventive clinicians, philanthropic institutions, category leading manufacturers and funded startups, helping them identify, invent and realize first-of-its-kind medical devices. The company has also created a strong internal pipeline of early-stage med-tech IP assets which we are now outlicensing and commercialising through global partners and collaborators.